Endpoint Health
Dr. Varney is the former head of Genentech’s Research and Early Development and a member of the Roche Executive Committee. He was recruited to Genentech to build its small molecule discovery capability, which now accounts for more than 40 percent of the company’s development portfolio, including the marketed anticancer agents Erivedge® and Cotellic®. Earlier in his career, Dr. Varney pioneered structure-based drug design as a founding employee at Agouron, which delivered Viracept® and resulted in the discovery of several currently marketed anticancer agents, including Xalkori® and Inlyta®. In 2018, Dr. Varney was also named Hero of Chemistry in 2018 by the American Chemical Society.
This person is not in the org chart
This person is not in any offices
Endpoint Health
Endpoint Health's mission is to address urgent needs in immune-driven critical and chronic illnesses by delivering therapies that are personalized to each patient’s biology.